acetylleucyl-leucyl-norleucinal

Summary

Acetylleucyl‑leucyl‑norleucinal (ALLN) is a synthetic peptide‑based inhibitor of the proteasome and related cysteinyl proteases. In research settings it is employed to block proteolytic degradation of proteins such as apolipoprotein B, thereby influencing very‑low‑density lipoprotein (VLDL) assembly in hepatic cells.

Mechanism of Action

ALLN binds to the active sites of the 20S proteasome and other cysteine‑type proteases, forming a reversible covalent adduct that blocks peptide bond hydrolysis. By inhibiting these enzymes it prevents the rapid intracellular degradation of nascent apolipoprotein B, allowing more apoB to be incorporated into assembling VLDL particles within the endoplasmic reticulum.

What the Research Shows

A 2003 study using HuH‑7 human hepatoma cells showed that verapamil reduced secretion of apoB‑containing lipoproteins by promoting apoB degradation. Adding ALLN restored apoB recovery, indicating that proteasome‑ and cysteinyl‑protease‑mediated degradation limits VLDL assembly when lipid supply is low. The paper also described a verapamil‑sensitive, non‑microsomal triglyceride transfer step, but ALLN’s role was limited to protease inhibition. No in‑vivo data were reported.

Reported Benefits

Evidence from the cell‑culture experiment suggests that ALLN can preserve apoB levels and may be useful for probing the proteolytic control of VLDL formation. Its ability to block proteasome activity makes it a valuable tool for dissecting protein turnover pathways in hepatic lipid metabolism research.

Limitations of the Evidence

Findings are confined to a single in‑vitro model; there are no animal or clinical studies evaluating efficacy, pharmacokinetics, or therapeutic relevance. Proteasome inhibition is broad and can affect many cellular processes, so results may not translate to whole‑organism physiology. The compound’s effects on other pathways remain uncharacterized.

Safety Considerations

ALLN is a research‑grade protease inhibitor with no established safety profile for humans. Proteasome inhibition can induce cytotoxicity, apoptosis, and immune modulation in cultured cells. Consequently, it should be handled with standard laboratory protective measures and not used in clinical contexts.

How It Is Administered

In research, ALLN is added directly to cell‑culture media for in‑vitro experiments. Animal studies have employed intraperitoneal, intravenous, or subcutaneous injections, but detailed dosing regimens are not provided in the literature.

Routes of Administration

Goals & Uses

• Proteasome inhibition (research)Ubiquitin Proteasome PathwayHigh
• NF-κB pathway studySignal Transduction ResearchModerate
• Cathepsin inhibition (research)Lysosomal Protease InhibitionModerate
• Proteasome inhibition in vitroResearch ToolModerate
• Protease inhibitionResearch ToolHigh
• Apoptosis researchCell Death BiologyModerate
• Apoptosis induction studiesResearch ToolModerate
• Calpain inhibition (research)Protease InhibitionHigh

Contraindications

• Human therapeutic useRegulatory/safetyHigh

Adverse Effects

• Off-target protease inhibitionPharmacologicalCommon
• ER stress inductionCell BiologyUncommon
• CytotoxicityCell ViabilityCommon

Drug Interactions

• Other proteasome inhibitors (e.g., MG-132, bortezomib)High
• Cysteine protease substrates/assaysModerate

Population Constraints

• In vivo / human useSafetyAbsolute

Regulatory Status

• European UnionUnapprovedNo marketing authorization in the European Union.
• United StatesUnapprovedNot an FDA‑approved therapeutic; supplied as a research chemical.
• United KingdomUnapprovedNot licensed for clinical use in the United Kingdom.

Not approved for human therapeutic use; classified as a research chemical.

Evidence & Sources

• Transmembrane lipid transfer is crucial for providing neutral lipids during very low density lipoprotein assembly in endoplasmic reticulum
  Journal ArticleLowHigashi Y, et al.2003-01-01T00:00:00.000000Z

Frequently Asked Questions